Liu Xinyu, Zhang Wei, Ma Baofeng, Lv Chunlei, Sun Mimi, Shang Qinghua
College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Department of Liver Disease, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China.
Front Physiol. 2024 Oct 30;15:1382293. doi: 10.3389/fphys.2024.1382293. eCollection 2024.
The early detection and intervention of liver fibrosis (LF) in patients with chronic liver disease is critical to their management. The accuracy of serum Mac-2 binding protein glycosylation isomer (M2BPGi) in the diagnosis of LF remains controversial. This study aimed to comprehensively assess the value of serum M2BPGi in diagnosing LF.
The PubMed, Embase, MEDLINE, Web of Science, and Cochrane Library databases were searched. The effect values were combined using a random-effects model. Meta-regression and subgroup analysis were used to explore the sources of heterogeneity. In addition, publication bias assessment and sensitivity analysis were conducted.
This study includes 12 studies with 2,416 patients. The pooled sensitivity, specificity, and AUROC of M2BPGi in the diagnosis of significant fibrosis (≥F2) were 0.65 (95% CI: 0.57-0.71), 0.79 (95% CI: 0.72-0.84), and 0.78 (95% CI: 0.74-0.81), respectively, while those for predicting extensive fibrosis (≥F3) were 0.76 (95% CI: 0.71-0.80), 0.75 (95% CI: 0.68-0.81), and 0.81 (95% CI: 0.77-0.84). Sensitivity analysis indicated stable results in this study. The disease type, cut-off values, study country, average age, and male proportion were the sources of heterogeneity in diagnosing significant fibrosis of M2BPGi ( < 0.05). Sample size, disease type, study country, publication year, cut-off values, average age, and male proportion were important sources of heterogeneity in diagnosing extensive fibrosis ( < 0.05).
Serum M2BPGi has good diagnostic performance for significant fibrosis and extensive fibrosis in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), or nonalcoholic fatty liver disease (NAFLD) and is an effective, non-invasive, and convenient marker.
慢性肝病患者肝纤维化（LF）的早期检测和干预对其治疗至关重要。血清Mac-2结合蛋白糖基化异构体（M2BPGi）在LF诊断中的准确性仍存在争议。本研究旨在全面评估血清M2BPGi在LF诊断中的价值。
检索PubMed、Embase、MEDLINE、Web of Science和Cochrane图书馆数据库。采用随机效应模型合并效应值。采用Meta回归和亚组分析探讨异质性来源。此外，进行了发表偏倚评估和敏感性分析。
本研究纳入12项研究，共2416例患者。M2BPGi诊断显著纤维化（≥F2）的合并敏感性、特异性和曲线下面积（AUROC）分别为0.65（95%CI：0.57 - 0.71）、0.79（95%CI：0.72 - 0.84）和0.78（95%CI：0.74 - 0.81），而预测广泛纤维化（≥F3）的合并敏感性、特异性和AUROC分别为0.76（95%CI：0.71 - 0.80）、0.75（95%CI：0.68 - 0.81）和0.81（95%CI：0.77 - 0.84）。敏感性分析表明本研究结果稳定。疾病类型、临界值、研究国家、平均年龄和男性比例是M2BPGi诊断显著纤维化异质性的来源（<0.05）。样本量、疾病类型、研究国家、发表年份、临界值、平均年龄和男性比例是诊断广泛纤维化异质性的重要来源（<0.05）。
血清M2BPGi对慢性乙型肝炎（CHB）、慢性丙型肝炎（CHC）或非酒精性脂肪性肝病（NAFLD）患者的显著纤维化和广泛纤维化具有良好的诊断性能，是一种有效、无创且便捷的标志物。
